UPC_CFI_124/2024

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Einstweilige MaßnahmenEinstweilige MaßnahmenHamburg LDProvisional measuresCase Closed

Übersicht Entscheidungen Begründung Zitate Dokumente Zeitverlauf

Parteien

Kläger

Alexion Pharmaceuticals, Inc.(AstraZeneca Group)

Vertreter: Elena Hennecke

Beklagte

Amgen Technology (Ireland) Unlimited Company(Amgen Group)

Richter

Sabine Klepsch
Alima Zana
Stefan Schilling
Rudi Goedeweeck

Patente

EP3167888

CPC-Codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sektor: Organic Chemistry

Ausgang

PI abgelehnt

Eingereicht: 19. März 2024

Erste Entscheidung: 26. Juni 2024

Sprache: English

The Hamburg Local Division dismissed Alexion Pharmaceuticals' application for a preliminary injunction against multiple Amgen entities based on EP 3 167 888, holding that while infringement could be established the court lacked sufficient certainty of patent validity given the EPO's repeated rejection of sequence correction attempts for SEQ ID NO:4.

Im UPC-Register öffnen